Pre-made Pagibaximab benchmark antibody (Whole mAb, anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-Staphylococcus epidermidis lipoteichoic acid therapeutic antibody (Pre-made Pagibaximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March?21[update], it is undergoing Phase II/III clinical trials.[1][2]
| Products Name (INN Index) | Pre-Made Pagibaximab Biosimilar, Whole Mab: Anti-Staphylococcus Epidermidis Lipoteichoic Acid therapeutic antibody |
|---|---|
| INN Name | pagibaximab |
| Target | Staphylococcus epidermidis lipoteichoic acid |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Staphylococcus epidermidis lipoteichoic acid |
| Package |
